Date:	--/--/-- --:--:--
Event Id:	E5KVF4DES
Action Type:	ACQUISITION
Action Status:	COMPLETED
Acquirer Symbol:
Target Symbol:	CNTA
Updated:	--/--/-- --:--:--
Purchase Price Per Share:	38
Price Per Share Currency:	USD
News References:	https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders-302808668.html

Action Notes

Eli Lilly and Company (NYSE: LLY) and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, today announced a definitive agreement for Lilly to acquire Centessa. Under the terms of the transaction agreement, Lilly will acquire all of the issued and to be issued share capital of Centessa (including the American Depositary Shares (ADSs) representing ordinary shares) for $38.00 in cash per share . The transaction, which will be effectuated by way of a scheme of arrangement under the laws of England and Wales, is expected to close in the third quarter, subject to approval by Centessa shareholders, sanction by the High Court of Justice of England and Wales and satisfaction of other customary closing conditions, including regulatory approvals.CNTA special meeting to vote on merger will be held 6/12/2026. UPDATE 6/22/2026: Closing of the Transaction will occur and the Scheme will become effective upon the Court Order being delivered to the Registrar of Companies, which is expected to occur on June 24, 2026. The last day of trading of Centessa American Depositary Shares ("ADSs") on Nasdaq is expected to be tomorrow, June 23, 2026, with trading in Centessa ADSs on Nasdaq being halted before the opening of trading on June 24, 2026.